Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

ed transaction enables Angiotech to

raise a sizable amount of gross proceeds in the form of convertible

securities that will bear non-cash interest payable in kind, and will

be convertible into shares of Angiotech's newly formed subsidiary,

API. The net proceeds that the Company elects to raise will be

utilized to reduce selected principal amounts of the two cash pay

debt securities of Angiotech currently outstanding, significantly

reducing Angiotech's cash interest expense and thereby improving

interest coverage and debt ratios.

- Retain majority API stake for Angiotech shareholders. This

transaction leaves a pro forma API initial ownership stake of between

52% and 68% for Angiotech's existing shareholders (measured

accounting for the convertible notes on an "if converted" basis at

closing). Importantly, Angiotech's existing shareholders will

continue to participate meaningfully in the success of the various

API businesses and product opportunities, including API's proprietary

Quill SRS(TM) technology and its recently approved

5-flourouracil-eluting central venous catheter.

- Mitigates risks related to Angiotech's drug-eluting stent royalty

revenue and cash flows. The debt and cash interest expense reduction

that may be achieved, combined with the significant implied equity

value of Angiotech's ownership stake in API, should improve

Angiotech's ability to continue to meet its debt obligations should

royalties received from its partner Boston Scientific Corporation

("BSC") decline from current levels as a result of additional

competitive entrants into the market for drug-eluting stents.

- Unlock and capture value embedded in Angiotech's non-TAXUS assets.

The conversion ratio of the securities issued impl
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 In contrast to traditional LED ... various colors, Valoya uses proprietary LED technology to incorporate ... possible uniformity which is critical in low proximity installations. ... accuracy throughout its lifetime which is up to four ... , "The investment cost was clearly higher when compared ...
(Date:12/19/2014)... -- Egenix, Inc. is pleased to announce that Lionel ... to succeed Donald Fresne ; Mr. Fresne has also ... member of the Board.  In recognition of the many contributions ... almost twenty years, the Board designated Mr. Fresne as Chairman ... a Search Committee to find a suitable replacement with Biotech ...
(Date:12/17/2014)... 17, 2014 Based on the ... surgical imaging market is dominated by four major ... imaging market. These players include GE Healthcare (U.K.), ... (Germany). , Full Report Copy at ... Healthcare can be attributed to its strong product ...
(Date:12/17/2014)... 17, 2014 Once more, EMAAR ... larger packaged waste water treatment plant to phase one ... City (KAEC). Two years ago Bioshaft successfully supplied and ... serving two residential towers with an occupancy of 900 ... quarter million gallons per day and was signed on ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... (Nasdaq: MNKD ), focused on discovering, developing and,commercializing ... present at the Wachovia Healthcare Conference on January 30, ... Boston, MA., Interested parties can access a link ... Investor Relations section of the Company,s website at, http://www.mannkindcorp.com ...
... a biotechnology company discovering and developing the next wave of,antibody therapeutics, today ... year end 2007 results at 8:00 a.m. (Eastern,Time) on Tuesday, January 29, ... issued at 7:00 a.m. prior to the call., DATE: ... Tuesday, January 29, 2008, TIME: ...
... Jan. 25 AMDL, Inc. (Amex:,ADL), headquartered ... and Jilin China, through its wholly owned ... company that, together,with Jade, engages in the ... care and diagnostic products. It today,announced that ...
Cached Biology Technology:ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call 2AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000 2
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Chase, MD Maintaining adequate levels of vitamin D can help ... according to a recent study accepted for publication in The ... ( JCEM ). The study of more than 10,000 ... absorbed more vitamin D into their bodies. Vitamin D is ...
... NY) Researchers at Albert Einstein College of ... strategy for preventing infections due to the highly common ... herpes (herpes simplex virus 2) and cold sores (herpes ... The FASEB Journal , could lead to new drugs ...
... nature reserves and wetlands of the semi-arid wheatbelt of ... fauna are the backdrop for new research to improve ... The project will combine the latest ideas ... the pioneering ambitions of forward-thinking Australian environmental planners. ...
Cached Biology News:Vitamin D benefits breathing in tuberculosis patients 2Einstein study reveals new approach for stopping herpes infections 2Nottingham-Australia collaboration on environmental conservation of the future 2Nottingham-Australia collaboration on environmental conservation of the future 3
Apoptosis Detection Systems and Reagents...
... rodent oral gavage feature soft rubber tips ... trauma. Plus they are disposable, to eliminate ... of cross-contamination. Diameter: ... Length: ...
Bovine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11:...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Biology Products: